NOVO.B.DK

288.45

+1.26%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

AMBUB.DK

68.15

+1.34%↑

NOVO.B.DK

288.45

+1.26%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

AMBUB.DK

68.15

+1.34%↑

NOVO.B.DK

288.45

+1.26%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

AMBUB.DK

68.15

+1.34%↑

NOVO.B.DK

288.45

+1.26%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

AMBUB.DK

68.15

+1.34%↑

NOVO.B.DK

288.45

+1.26%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

AMBUB.DK

68.15

+1.34%↑

Kodu・Aktsiate loetelu・Zealand Pharma A-S

Zealand Pharma A-S

Suletud

316.7 0.44

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

315.5

Max

317.9

Põhinäitajad
By Trading Economics
Sissetulek	-15M -394M
Müük	-35M 34M
P/E Sektori keskmine	3.498 49.701
Aktsiakasum	-5.58
Kasumimarginaal	-1,158.824
Töötajad	544
EBITDA	-26M -529M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+25.15% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	13. aug 2026

Turustatistika
By TradingEconomics
Turukapital	918M 22B
Eelmine avamishind	316.26
Eelmine sulgemishind	316.7

Zealand Pharma A-S Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. märts 2026, 09:24 UTC

Suurimad hinnamuutused turgudel

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

1. okt 2025, 08:54 UTC

Suurimad hinnamuutused turgudel

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

6. märts 2026, 07:22 UTC

Market Talk

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Zealand Pharma A-S Prognoos

Hinnasiht

By TipRanks

25.15% tõus

12 kuu keskmine prognoos

Keskmine 270.582 DKK 25.15%

Kõrge 270.568 DKK

Madal 270.568 DKK

Põhineb 1 Wall Streeti analüütiku instrumendi Zealand Pharma A-S 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Zealand Pharma A-S aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.